Novartis: all 3,900 studies
Page 23 of 39. Open to participants first (226), then studies with results posted, then the rest; newest registration first within each.
- Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world SettingTerminatedNCT05266495
- Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the GulfCompletedNCT05266469
- A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)CompletedNCT05252585Phase 4
- Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and DolutegravirCompletedNCT05236530Phase 1
- A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular DegenerationCompletedNCT05230537Phase 2
- Managed Access Programs for PKC412, MidostaurinNo longer availableNCT05219266
- A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®Active, not recruitingNCT05217810
- Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPPCompletedNCT05215561
- Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).WithdrawnNCT05206591Phase 3
- Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)TerminatedNCT05203419Phase 1
- Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.Active, not recruitingNCT05201066Phase 2
- Investigate Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation and the Food Effect of Alpelisib Granule Formulation in Adult Healthy VolunteersCompletedNCT05195892Phase 1
- Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims DataCompletedNCT05177406
- PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple MyelomaTerminatedNCT05172596Phase 2
- CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic LeukemiaWithdrawnNCT05168748Phase 1
- Roll-over Study to Allow Continued Access to RibociclibActive, not recruitingNCT05161195Phase 4
- XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United StatesCompletedNCT05157087
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT05156281Phase 3
- A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.CompletedNCT05155709Phase 1
- 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial SpondyloarthritisCompletedNCT05155098
- Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 InhibitorsCompletedNCT05153135
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)Active, not recruitingNCT05147220Phase 3
- Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)CompletedNCT05146687
- A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and AtezolizumabActive, not recruitingNCT05142696Phase 1/2
- Impact of Fingolimod Adherence on OutcomesCompletedNCT05141669
- A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 InhibitorsCompletedNCT05141240
- Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerTerminatedNCT05132075Phase 3
- Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisActive, not recruitingNCT05126277Phase 3
- Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.CompletedNCT05124925Phase 2
- An Observational Prospective Study to Characterize Patients Initiating Enerzair® Breezhaler®, With or Without Sensor, as a Maintenance Treatment for AsthmaWithdrawnNCT05120986
- Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed DyslipidemiaCompletedNCT05118230
- Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in JapanCompletedNCT05114746Phase 2
- Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical PracticeTerminatedNCT05112835
- Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)CompletedNCT05111743
- Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)CompletedNCT05110209
- A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.Active, not recruitingNCT05109728Phase 1
- MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast CancerNo longer availableNCT05108740
- Managed Access Programs for LDK378, CeritinibNo longer availableNCT05100134
- A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records DataCompletedNCT05096143
- Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment ModelsCompletedNCT05096039
- A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) ElevationActive, not recruitingNCT05090371Phase 4
- Characterizing the Use of Ofatumumab in a Real World SettingCompletedNCT05090033
- Drug-drug Interaction Study of Ganaplacide and Lumefantrine With ItraconazoleCompletedNCT05084651Phase 1
- Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)CompletedNCT05082415
- Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.CompletedNCT05078580Phase 1
- Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using AlpelisibCompletedNCT05073120
- Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common ColdWithdrawnNCT05070650Phase 3
- A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate CancerActive, not recruitingNCT05067140Phase 1/2
- Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services ProgramCompletedNCT05066685
- A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With MyelofibrosisCompletedNCT05044026
- Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.Active, not recruitingNCT05038735Phase 3
- Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of BroluciumabCompletedNCT05037396
- Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseaseActive, not recruitingNCT05030428Phase 3
- Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy ParticipantsCompletedNCT05026996Phase 1
- Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-worldCompletedNCT05022342
- Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and IndiaTerminatedNCT05020873
- Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic ImpairmentCompletedNCT04993157Phase 1
- Regulatory Post-Marketing Surveillance Study for BrolucizumabCompletedNCT04985487
- Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)Active, not recruitingNCT04980833Phase 2
- A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world SettingTerminatedNCT04967248
- Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.CompletedNCT04961619
- Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled AsthmaTerminatedNCT04946318Phase 2
- A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in KoreaCompletedNCT04946305
- A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in RussiaCompletedNCT04943497
- Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg PenCompletedNCT04940065
- Russian Registry of Patients With nAMDTerminatedNCT04935411
- Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)CompletedNCT04930094Phase 3
- Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple SclerosisActive, not recruitingNCT04926818Phase 3
- Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaActive, not recruitingNCT04925479Phase 1/2
- Global Managed Access Program Cohort for Ligelizumab in CSUNo longer availableNCT04903613
- Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin LymphomaTerminatedNCT04903197Phase 1
- Study of Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy ParticipantsTerminatedNCT04896632Phase 1
- DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other MalignanciesTerminatedNCT04895748Phase 1
- Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional StudyTerminatedNCT04895202
- A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in ChinaCompletedNCT04894890
- Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor TherapyCompletedNCT04889430Phase 3
- Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPDCompletedNCT04882124Phase 2
- A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid TumorsActive, not recruitingNCT04857372Phase 1
- Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved IndicationsCompletedNCT04847895
- A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With OfatumumabCompletedNCT04847596
- 177Lu-PSMA-617 Managed Access Program for mCRPC PatientsNo longer availableNCT04825652
- Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDSTerminatedNCT04810611Phase 1
- Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion DependenceActive, not recruitingNCT04797000Phase 2
- Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase InhibitorsCompletedNCT04795427Phase 2
- Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMSCompletedNCT04788615Phase 3
- Proof of Concept Study of Binocular Videogames Versus Patching for AmblyopiaTerminatedNCT04784390Phase 1
- Special Drug Use Surveillance for Entresto TabletsCompletedNCT04781881
- Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-CCompletedNCT04774003Phase 1
- Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056WithdrawnNCT04771143Phase 1
- Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)Active, not recruitingNCT04765657Phase 3
- Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in PortugalTerminatedNCT04764656
- Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal HemoglobinuriaActive, not recruitingNCT04747613Phase 3
- Managed Access Programs for INC280, CapmatinibNo longer availableNCT04741789
- Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in IndiaCompletedNCT04735354
- Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETsCompletedNCT04727723
- Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.TerminatedNCT04712721Early Phase 1
- VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)TerminatedNCT04702425Phase 1
- Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationActive, not recruitingNCT04699188Phase 1/2
- Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)WithdrawnNCT04697953Phase 3
- Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCLCompletedNCT04697160